Don't Routinely Recommend Repatha (Evolocumab) for High Cholesterol

Repatha (rih-PATH-ah, evolocumab) is the first "PCSK9 inhibitor" approved for high cholesterol in Canada.

It works by preventing PCSK9...proprotein convertase subtilisin/kexin type 9...from binding and degrading liver LDL receptors. This leads to more LDL receptors...and more LDL cholesterol clearing from the blood.

Repatha can lower LDL about 60% in patients already receiving maximum statin doses.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote